Patient description: The patient is a 41-year-old obese woman coming to the emergency room with abdominal pain and vomiting. The pain that started gradually yesterday is located in the epigastric and periumbilical regions, radiating to her back. She drinks alcohol frequently and does not smoke. She has no history of allergies and uses only multivitamins daily. Her family history is positive for hypertension (her mother). She lives with her husband and has 3 children. The abdomen is tender and soft. Her bowel sounds are normal. Her heart rate is 115/min and blood pressure 110/75 mmHg. The lab studies are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glucose level of 15. Her abdominal CT scan revealed acute edematous interstitial pancreatitis with enlarged common bile duct and intrahepatic duct confirming gall stone pancreatitis. Her pregnancy test is negative and she is not breastfeeding.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Obesity adults 18 year or older with BMI ≥30 and ≤40 kg/m2, and a diagnosis of type 2 diabetes  Symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease 2. Previous bariatric or gastric surgery 3. History of chronic or acute pancreatitis 4. History of small bowel obstructions 5. History of open abdominal and/or pelvic surgery open appendectomy with a right lower quadrant incision. 6. Thyroid or adrenal disease not controlled with medication 7. History of/or signs and/or symptoms of esophageal, gastric, or duodenal disease such as dysphagia and/or painful swallowing, hiatal hernias >5 centimeter, paraesophageal hernias, chronic or acute inflammation, cancer, varices, diverticula, gastroparesis, ulcers, stricture/stenosis, or achalasia 8. Specific diagnosed genetic or hormonal cause for obesity such as Prader-Willi syndrome 9. Severe coagulopathy, hepatic insufficiency or cirrhosis 10. Unable or unwilling to discontinue use of aspirin and/or non-steroidal anti-inflammatory agents (NSAIDs) at least 14 days prior to Elipse deployment and continuing for 14 days after Elipse excretion 11. Anemia defined as either Hgb <11 g/dL for females and <12 g/dL for males 12. Inability to walk 200 meters without assistance 13. Eating disorders including night eating syndrome (NES), bulimia, or binge eating disorder 14. Current or history of illicit drug use or excessive alcohol use 15. Currently taking the following medications (within 30 days prior to enrolment) and/or anticipated need for these medications during the study: Systemic corticosteroids; anticoagulants (e.g. warfarin, dabigatran) or anti-platelet therapy; narcotics or opiates; anti-seizure medication (e.g. clonazepam, phenytoin) 16. Serum autoantibodies against glutamic acid decarboxylase (GAD) or tyrosine phosphatase (IA2) (MODY or type 1 diabetes) 17. Any specified conditions that, in the opinion of the investigator, may render the subject unable to complete the study without a likely fatal outcome, or lead to difficulties for subject compliance with study requirements, or could confound study data. 18. Women in childbearing age must document a negative pregnancy test. Women must not be breast-feeding at the time of treatment